Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

Core Insights - Fennec Pharmaceuticals has presented new real-world data supporting the use of PEDMARK (sodium thiosulfate injection) in adults with head and neck cancers, indicating its safe administration at least six hours after cisplatin treatment without compromising the drug's antitumor efficacy [1][2][5] - The findings highlight the potential of PEDMARK to mitigate cisplatin-induced hearing loss, a significant survivorship issue, with most high-risk patients showing no measurable hearing loss during or after treatment [1][4][5] Company Overview - Fennec Pharmaceuticals is focused on the commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in cancer patients, having received FDA approval in September 2022 and subsequent approvals in Europe and the UK [22][24] - The company has entered into an exclusive licensing agreement with Norgine Pharmaceuticals for the commercialization of PEDMARQSI in Europe, the UK, Australia, and New Zealand [23] Industry Context - Cisplatin is widely used in treating solid tumors but is associated with a high incidence of hearing loss, affecting 60-90% of patients depending on treatment parameters [7][8] - The introduction of PEDMARK represents a significant advancement in addressing the long-term quality of life issues faced by cancer survivors due to treatment-induced hearing loss [12][9]